Introduction/Background Because of its asymptomatic progression,ovarian cancer is mainly encountered in advanced stages in women.The standard treatment for ovarian cancer is cytoreductive surgery and chemotherapy with a platinum-taxane combination.Diaphragm peritonectomy,splenectomy,liver resection are among the procedures for the cytoreduction of ovarian cancer that have been reported to be both feasible and associated with acceptable morbidity.

This study aims to evaluate the characteristics,treatment process,survival outcomes of patients who underwent aggressive cytoreductive surgery to achieve optimal cytoreduction in ovarian cancer.

Methodology This study was a retrospective analysis involving patients with epithelial ovarian cancer who underwent cytoreductive surgery by a single gynecologist oncologist between November 2014 and September 2022 in a single center.In the study, aggressive cytoreduction was defined anatomically as debulking of disease proximal to the ligament of Treitz. The patients who underwent aggressive surgery were included in Group 1,and those who did not receive aggressive surgery were included in Group 2.

Results The patients in Group 1 have received more cycles of chemotherapy (p=0.028).The study population’s median progression-free survival (PFS) was 11.8 months,the mean overall survival (OS) was 67.3 months.Median PFS was determined as 11.3 months for Group 1 and 12.2 months for Group 2.No statistically significant difference was observed between the two groups regarding median PFS(p=0,593).Mean OS was 46.2 months for Group 1 and 75.6 months for Group 2.The Mean OS of Group 2 was statistically significantly more extended than Group 1(p=0.011).

Conclusion We aimed to analyze the effect of aggressive surgery on the survival outcomes of ovarian cancer patients.We did not observe a clear benefit of aggressive surgery since the PFS results were similar in the two groups of patients.The longer OS in Group 2 might result from subsequent treatments,including surgery,single-agent chemotherapy, and combined chemotherapy regimens.Although there was a limited number of patients in our study, this data will contribute to the literature.

Disclosures None.